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Disruptions in metal ion homeostasis have been described in association with amyotrophic
lateral sclerosis (ALS) for a number of years but the precise mechanism of involvement is
poorly understood. Metal ions are especially important to familial ALS cases caused by
mutations in the metalloenzyme copper-zinc superoxide dismutase (SOD1). To investigate
the role of metals in aggregation of mutant SOD1, we have examined the localization
of metal ions in a cell culture model of overexpression. Chinese hamster ovary cells
(CHO-K1) were transfected to overexpress SOD1 fused to yellow fluorescent protein (YFP)
to readily identify the transfected cells and the intracellular aggregates that develop in
the cells expressing mutant or wild-type (WT) SOD1. The concentration and distribution
of iron, copper, and zinc were determined for four SOD1 mutants (A4V, G37R, H80R,
and D125H) as well as a WT SOD1 using X-ray fluorescence microscopy (XFM). Results
demonstrated that the SOD1 aggregates were metal-deficient within the cells, which is
consistent with recent in vitro studies. In addition, all SOD1 mutants showed significantly
decreased copper content compared to the WT SOD1 cells, regardless of the mutant’s
ability to bind copper. These results suggest that SOD1 overexpression creates an unmet
demand on the cell for copper. This is particularly true for the SOD1 mutants where copper
delivery may also be impaired. Hence, the SOD1 mutants are less stable than WT SOD1
and if copper is limited, aggregate formation of the metal-deficient, mutant SOD1 protein
occurs.
Keywords: amyotrophic lateral sclerosis, superoxide dismutase, X-ray fluorescence microscopy, synchrotron
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ease that affects more than 30,000 people annually in the US,
making it the most common motor neuron disease (Bruijn
et al., 2004). ALS begins with muscle weakness that develops
into progressive paralysis and eventually leads to death, which
generally occurs within 2–5 years of the disease diagnosis. There
is currently no known cure for the disease and the limited
treatments available do not significantly alter the course of the
disease (Miller et al., 2007). Approximately 90% of all ALS cases
are sporadic in nature with no known cause. The remaining
10% have a genetic link and are known as familial ALS cases.
One such form of familial ALS, which accounts for 2.5% of
all ALS cases, is caused by mutations in the gene that codes
for the antioxidant protein copper-zinc superoxide dismutase
(SOD1).
SOD1 is a metalloenzyme that binds one copper ion and one
zinc ion per monomer for the protein’s activity and stability,
respectively (Ellerby et al., 1996). There are over 160 known
mutations in SOD1 that can cause ALS (Lill et al., 2011; Abel et al.,
2013). Despite extensive research, it is currently not understood
how such a large distribution of mutations and their properties
can all result in the same disease. These mutations are dis-
tributed throughout the protein and result in SOD1 mutations
with dramatically varied biochemical properties, such as metal
binding affinity and antioxidant activity levels. Thus, mutations
are classified into two distinct categories: metal binding region
(MBR) mutations, which directly affect the protein’s ability to
bind metal causing diminished activity levels, and wild type-
like (WTL) mutations, which maintain metal binding ability and
have activity levels similar to that of the wild-type (WT) protein
(Hayward et al., 2002; Rodriguez et al., 2002). In this study, four
SOD1 mutations were evaluated, including WTL mutations (A4V
and G37R) and MBR mutations (H80R and D125H). The A4V
mutation occurs at the SOD1 dimer interface and has very low
stability (Deng et al., 1993; Hayward et al., 2002), whereas the
G37R mutation is in an electrostatic loop and has much higher
stability (Borchelt et al., 1994). The H80R mutation is found
in the zinc-binding region, hence zinc binding is diminished
(Seetharaman et al., 2010). Since the ability of SOD1 to bind
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copper is thought to be dependent on its ability to bind zinc first,
this mutation is also deficient in copper. The D125H mutation
occurs in a charged loop that helps coordinate the metal binding
site (Hayward et al., 2002). While it does not directly affect metal-
binding, this mutation severely diminishes metal binding affinity
and results in a protein with low stability.
Metals have been implicated in a number of neurodegenerative
diseases including ALS (Bush, 2003; Maynard et al., 2005; Vonk
and Klomp, 2008). When improperly regulated, metal ions such
as copper and zinc can be highly toxic to the cells. Copper is espe-
cially dangerous due to its catalytic activity and redox potential,
resulting in the production of damaging reactive oxygen species
(ROS), which lead to the propagation of oxidative stress found
in patients with ALS (Bruijn et al., 2004; Lutsenko et al., 2010).
Alterations in zinc concentrations can also cause problems such as
glutamate excitotoxicity, in which excess zinc over stimulates neu-
rons resulting in cell death (Smith and Lee, 2007). Interestingly,
Riluzole, the only approved drug for the treatment of ALS, reduces
excitotoxicity by inhibiting glutamate release (Doble, 1996). Thus,
proper metal homeostasis is critical to maintaining a healthy
cellular environment and delaying disease progression.
A common pathological feature of SOD1-ALS is the formation
of misfolded SOD1 aggregates in the spinal cord motor neurons
that form concomitantly with the onset of paralysis. Protein
aggregates are found in several other neurological diseases, such
as the amyloid-β plaques found in Alzheimer’s disease (AD) and
Lewy bodies composed of α-synuclein in Parkinson’s disease (PD;
Selkoe, 2003, 2004; Soto, 2003, 2013). The role of these aggregates
in disease has been the subject of great debate for a number of
years. Originally, aggregates were thought to be the source of
toxicity in these diseases. However, it has also been suggested
that the aggregates are a cellular response to sequester toxic
soluble proteins, avoiding further damage from the misfolded and
aberrant proteins (Lee et al., 2002).
The mechanisms of aggregation are not well understood,
but metal ions have been implicated. For example, it has been
observed that metals can aid in the precipitation and aggregation
of amyloid-β (Huang et al., 1997) and α-synuclein (Bertoncini
et al., 2005). It was recently shown that the SOD1 aggregates
found in a mouse model of SOD1-ALS are composed of unmodi-
fied and nascent SOD1 (Shaw et al., 2008). Nascent and unmetal-
lated SOD1 mutants are relatively unstable compared to nascent
WT SOD1, suggesting that mutants are more prone to aggregation
than WT SOD1 (Rodriguez et al., 2002, 2005).
In this study, we used X-ray fluorescence microscopy (XFM)
to image the metal ion distribution and the metallation state
of the SOD1 aggregates in Chinese hamster ovary (CHO-K1)
cells overexpressing WT SOD1 or mutant SOD1 (A4V, G37R,
H80R and D125H). XFM is a spectroscopic technique that can
be used to determine the concentration and distribution of metal
ions in biological cells and tissues. To visualize the transfected
cells and the aggregates, SOD1 was fused in-frame with yellow
fluorescent protein (YFP) (Prudencio et al., 2009; Qualls et al.,
2013a,b). Results showed that the SOD1 aggregates were metal-
deficient within the cells, which is similar to the detergent-
insoluble aggregates isolated from a transgenic mouse model of
SOD1-ALS (Lelie et al., 2011). In addition, we found that cells
with mutant SOD1 contained a lower level of copper compared
to cells expressing WT SOD1, regardless of whether the SOD1
mutant was capable of binding copper. These results were surpris-
ing and suggest that copper transport is affected regardless of the
SOD1 mutation.
MATERIALS AND METHODS
Chinese hamster ovary cells (CHO-K1) (ATCC, Manassas, VA)
were maintained in F12-K media with 10% fetal bovine serum,
1% penicillin/streptomycin, and 1% amphotericin- β. The cells
were stored in an incubator at 37◦C and 5% CO2. Cells were
seeded onto 2.5 × 2.5 mm silicon nitride windows (Silson,
UK), an IR and X-ray transparent material, with a 500 nm
membrane thickness. After 20 h, when the cells were approxi-
mately 80% confluent, they were transfected with plasmid cDNA
(Karch et al., 2009) using lipoD293 transfection reagent (Sig-
naGen, Rockville, MD) according to the protocol provided by
SignaGen. CHO-K1 cells were transfected to express a WT or
mutant (A4V, G37R, H80R, or D125H) form of SOD1 fused
to a YFP tag to visualize the transfected cells and aggregates
without staining. The transfections were stopped between 19–
26 h, which was when YFP fluorescence was visible in most
cells and punctate aggregates could be seen (Prudencio et al.,
2009). The time to completion was varied so that the aggregate
levels would be equivalent for each mutation used. Cells were
fixed by rinsing the silicon nitride windows with PBS and then
dipping in cold (∼80◦C) methanol three times for 1 s each
time. The windows were allowed to dry at room temperature
and were stored in a desiccator until imaged. Each transfection
was carried out twice, and cells from both transfections were
imaged.
FTIR microspectroscopy was used to determine the protein
density of the aggregates. Spectra were acquired using a Thermo
Nicolet Continuum IR microscope coupled to beamline U2B at
the National Synchrotron Light Source (NSLS) at Brookhaven
National Laboratory (Upton, NY). A 32 × IR Schwarzchild
objective produced a 7 × 7 µm beam. A 4 cm−1 spectral res-
olution and 128 scans per spectrum were used over the mid-
infrared region (4000–800 cm−1). To normalize the additional
protein density found in the protein aggregates, 40–45 spectra
were collected both on the aggregates and off the aggregates
of transfected cells. For each spectrum, the protein content
was determined by integrating the Amide I band from 1610–
1700 cm−1 with a linear baseline from 1480 to 1800 cm−1.
The relative protein intensity was determined by calculating the
intensity ratio on the aggregates versus off the aggregates for each
cell.
The cells were then imaged with XFM at beamline 2-ID-E at
the Advanced Photon Source at Argonne National Laboratory
(Argonne, IL) to determine the distribution and concentration
of metal ions. The incident beam was tuned to 10 keV using a
Si(111) monochromator and the X-rays were focused to a 0.5 ×
0.5 µm spot size using 20 cm zone plates (Xradia, Pleasanton,
CA). The specimen was positioned at a 45◦ angle with respect
to the incident beam and maintained in a helium-purged box.
The X-ray fluorescence was detected with a four-element sili-
con drift detector oriented at 90◦ with respect to the incident
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beam and a differential phase contrast detector was used for the
transmitted X-ray beam. Approximately 15 cells were imaged per
mutation with a 0.5-s dwell time per point. A full energy disper-
sive spectrum was collected at each pixel. Metal concentrations
were determined based on NIST thin film standards 1832 and
1833.
To analyze the data, three regions of interest (ROI) were gen-
erated using the beamline’s MAPS program: (1) the nucleus; (2)
the cytoplasm; and (3) the aggregates (if present). The cytoplasm
ROI was separated from the nucleus to provide a more accurate
measure of metal concentrations in the cytoplasm where the
SOD1 is located. The aggregates were easily located using the
phase contrast images collected with the XFM data. In addition,
the aggregates were small (1–3 µm) so the 500 nm beam size
allowed for several pixels (approximately 10) from each aggregate
to be analyzed.
After generating ROIs, the data points within each ROI were
averaged and the aggregate values were normalized to the protein
density as determined by FTIR. Using the average values, a ratio
of the aggregate/cytoplasm was generated for copper and zinc to
demonstrate any change in metal content within the aggregates.
Statistics were performed on mean values from the ROIs of each
cell type with SPSS software (version 14.0) using the Kruskal-
Wallis non-parametric test. Significant groups were then tested
with Mann-Whitney U post-hoc test. Significance was determined
by p < 0.05.
RESULTS
Representative XFM and visible light images of the cells from
each group (WT, A4V, G37R, H80R, and D125H) are shown in
Figure 1. As can be seen, the iron concentration was higher in
the cytosol, while the zinc content was highest in the nucleus for
all cell types. The only statistically significant difference between
the cell types was found in the copper content in the cytoplasm.
Specifically, the WT cells contained approximately 24% more cop-
per than all of the SOD1 mutants (A4V, G37R, H80R and D125H)
as well as the untransfected cells (Figure 2). The mutant SOD1
cells also contained a smaller but significant (p> 0.05) increase in
copper compared to the untransfected cells. Interestingly, there
were no statistical differences between the mutant SOD1 cells,
regardless of metal-binding ability. Also, no trends were observed
in the zinc, iron, phosphorus, sulfur, potassium or calcium con-
centrations between the untransfected and transfected cells in the
cytoplasm or the nucleus.
FIGURE 1 | Epifluorescence images (first column) from SOD1-YFP
CHO-K1 cells with WT, A4V, G37R, H80R or D125H SOD1. XFM maps for
sulfur (second column), iron (third column), copper (fourth column), and zinc
(fifth column). The XFM images show the relatively large amounts of copper
and zinc found in the WT cells compared to the mutant SOD1 cells. Minimum
and maximum concentrations are in mM.
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FIGURE 2 | Bar graph of intracellular copper levels (excluding the
nucleus) for SOD1-YFP cells. Concentrations are in mM. The WT cells
contained the highest level of copper in comparison to the cells
overexpressing mutations in SOD1 and untransfected cells. All cells
overexpressing mutant SOD1 had significantly higher copper content than
the untransfected cells. * indicates significantly less than WT cells with p <
0.001.
Based on the FTIRM data, the aggregates showed a two-
fold increase in protein density compared to the surrounding
cytoplasm. Thus, the XFM data for the protein aggregates were
normalized by this factor to account for the greater amount of
material within the aggregates. Table 1 shows the ratio of aggre-
gate to cytoplasm concentrations for copper and zinc from cells
containing mutant SOD1-YFP (A4V, G37R, and H80R) aggre-
gates. Results showed that all of the aggregates of mutant SOD1-
YFP contained lower copper and zinc concentrations compared
to the surrounding area, suggesting that the aggregates are metal-
deficient. This trend was seen in both the WTL (A4V and G37R)
and MBR (H80R and D125H) mutations.
DISCUSSION
SOD1 AGGREGATES IN CELLS ARE METAL-DEFICIENT
The formation of SOD1 aggregates in the spinal cord is the
primary pathology found in ALS patients with SOD1 muta-
tions, but little is known about the aggregation process. The
precise mechanism of aggregate formation is needed in order
to gain an understanding of how aggregates impact disease pro-
gression. Cells transfected with mutant SOD1 develop intracel-
lular aggregates, similar to those found in ALS patients. The
results presented here show that the SOD1 aggregates in the
transfected cells are metal-deficient. This was true regardless of
the mutant’s ability to bind copper (WTL and MBR mutants).
These data also agree with a previous study that showed insol-
uble or aggregated SOD1 extracted from ALS mouse spinal
cords contained no metal (Lelie et al., 2011). These data sug-
gest that either the protein aggregated prior to being metal-
lated or that the process of aggregation resulted in a loss of
metal.
Table 1 | The ratio of aggregate/cytoplasm concentration for copper
and zinc in the SOD1 mutant cells.
Mutation Type Copper Zinc
A4V WTL 0.53 ± 0.13 0.34 ± 0.21
G37R WTL 0.45 ± 0.081 0.59 ± 0.27
H80R MBR 0.41 ± 0.041 0.31 ± 0.14
The aggregation of nascent SOD1 prior to metallation is also
supported by the very high stability of most metallated SOD1
mutations, making them less likely to aggregate once they are
metallated (Hayward et al., 2002; Rodriguez et al., 2002). In
contrast, apo-SOD1 is significantly less stable and contains large,
intrinsically disordered regions that make the protein much more
prone to aggregation (Rodriguez et al., 2005; Shaw and Valentine,
2007; Lelie et al., 2011).
In contrast to SOD1-ALS, protein aggregates found in other
neurodegenerative diseases, including amyloid-β plaques in AD
and Lewy bodies in PD, have been shown to have a high metal
content (iron, copper or zinc) (Selkoe, 2001; Lotharius and
Brundin, 2002; Leskovjan et al., 2009). For example, AD plaques,
which consist primarily of aggregated amyloid-β protein and form
in the brain of human patients, were found to be highly enriched
in metal (calcium, iron, copper and zinc) compared to the sur-
rounding brain tissue (Lovell et al., 1998; Miller et al., 2006).
However, in a mouse model of AD, it was found that the plaques
did not contain elevated metal ions (Leskovjan et al., 2009). This
has led to the hypothesis that AD plaques may accumulate metal
over time. For ALS, the studies presented here were limited to a
cell culture model of the disease. In the future, further studies
from the mouse model and/or human tissue will be needed to
determine if the mechanism of protein aggregation and the role of
metals is similar to other neurological diseases or unique to ALS.
COPPER CONCENTRATION IS LOWER IN CELLS OVEREXPRESSING
SOD1 MUTATIONS
The WT cells overexpressing SOD1 contained significantly more
copper than the untransfected cells. This increase in copper
content demonstrates that there is presumably enough copper
available to the cells to metallate the expressed WT SOD1.
To investigate the effects of mutant SOD1 on metal home-
ostasis, this study utilized two different types of SOD1 mutations
including WTL mutations (A4V and G37R), which are known to
bind copper and zinc, and MBR mutations (H80R and D125H),
which are unable to bind copper or zinc (Rodriguez et al., 2002,
2005; Valentine et al., 2005). Results showed that all mutations
contained approximately 24% less copper than the WT cells. In
addition, all mutants contained similar copper concentrations
regardless of metal-binding ability.
For WT SOD1, previous studies showed a reduced incorpo-
ration of copper when over-expressed in cell culture (Prudencio
et al., 2012). Here we show that the copper content in the WT
SOD1 cells is significantly higher than the untransfected cells, but
also suggests that that there is still an insufficient supply of copper
to metallate the overexpressed level of SOD1. For the mutant
SOD1 in this cell culture model, a substantial fraction of the
protein adopts a non-native conformation that remains soluble
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and freely mobile (Prudencio and Borchelt, 2011) and decreased
copper binding has also been observed (Ayers et al., 2014). Thus,
it is likely that the lower copper content in all the cells transfected
with mutant SOD1 is due to a combination of insufficient copper
delivery to the cells and inefficient copper binding to the active
site.
Delivery of copper to the cells is a highly regulated process.
Due to its potential redox activity, copper can be highly toxic
when not properly controlled. As a result, copper transporters and
chaperone proteins tightly regulate the concentration of copper
in the cell. Maintaining a strict copper balance is critical and
a disruption in homeostasis is implicated in several diseases,
including ALS (Gaggelli et al., 2006). For SOD1, copper is trans-
ported by the copper chaperone protein (CCS). CCS contains
an SOD1-binding domain that has approximately a 50% amino
acid sequence homology to SOD1, which is important for the
recognition and binding of SOD1 (Schmidt et al., 1999). All four
mutations examined in this study have residues that reside in the
homologous binding domain of CCS, which may prevent the effi-
cient binding of CCS to SOD1, possibly altering the transport of
copper. While CCS levels were not measured in this study, future
studies will address the question of copper transport directly.
Taken together, our results suggest a relationship between the
metal-deficient aggregates and the decreased copper found in
the cells overexpressing mutant SOD1. We suggest that SOD1
overexpression creates an added demand on the cell for Cu,
which is not met for the WT or mutant SOD1. In the mutant
SOD1, impaired copper transport to the protein may even further
reduce the copper content in the cell. Since the mutant proteins
are less stable than WT SOD1, and copper is less available,
aggregate formation of the metal-deficient mutant SOD1 protein
occurs.
One limitation of this work is that it utilized a cell culture
model, which does not always correlate with the disease in vivo.
That said, the data presented here agree with our previous stud-
ies on insoluble aggregates extracted from mouse spinal cords,
which were found to be metal-deficient. In the future, it will
be important to examine the metal content of these aggregates
directly within the spinal cord tissue of mouse models of SOD1-
ALS. Levels of the CCS and its ability to bring copper into
SOD1 also need to be assessed. Lastly, measuring aggregates in
human tissue would be the definitive experiment, but the SOD1
mutations account for a very small number of ALS cases (∼2.5%)
so the amount human tissue available is very limited. However,
it is clear that a combination of these studies would greatly
enhance our understanding of SOD1 metallation with respect to
ALS.
CONCLUSIONS
Both metal ion homeostasis and aggregate formation have been
implicated in the disease progression of ALS. This study used
a cell culture model of SOD1-ALS in order to examine metal
ion homeostasis and aggregate formation in a systematic man-
ner within the cellular environment. Results showed an increase
in copper content when WT SOD1 was overexpressed, which
decreased in cells transfected with mutant SOD1 showing a
disruption in copper homeostasis. Additionally, the aggregates
were found to be metal-deficient, supporting the hypothesis
that they form without metal-binding that stabilizes the protein.
Understanding the role that metals play in SOD1 aggregate can
lead to the development of improved drug treatments to prevent
aggregate formation and hopefully prevent the progression of the
disease.
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